Becton, Dickinson & Co.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0758871091
USD
193.76
0.19 (0.1%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Becton, Dickinson & Co. stock-summary
stock-summary
Becton, Dickinson & Co.
Pharmaceuticals & Biotechnology
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
Company Coordinates stock-summary
Company Details
1 Becton Dr , FRANKLIN LAKES NJ : 07417-1815
stock-summary
Tel: 1 201 8476800
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 191 Schemes (36.78%)

Foreign Institutions

Held by 516 Foreign Institutions (26.87%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Vincent Forlenza
Executive Chairman of the Board
Mr. Thomas Polen
President, Chief Executive Officer, Chief Operating Officer, Director
Mr. Marshall Larsen
Lead Independent Director
Ms. Catherine Burzik
Independent Director
Mr. R. Andrew Eckert
Independent Director
Ms. Claire Fraser
Independent Director
Mr. Jeffrey Henderson
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
5,509 Million
(Quarterly Results - Jun 2025)
Net Profit:
574 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 70,270 Million (Large Cap)

stock-summary
P/E

33.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.53%

stock-summary
Debt Equity

0.73

stock-summary
Return on Equity

7.79%

stock-summary
Price to Book

2.76